莫沙必利联合质子泵抑制剂治疗胃食管反流病疗效观察

Moser will benefit joint proton pump inhibitors in the treatment of gastroesophageal reflux disease curative effect observation

目的:探究莫沙必利联合质子泵抑制剂治疗胃食管反流病的临床疗效。方法:选取2014年2-8月期间我院收治的60例胃食管反流病患者作为研究对象,将其随机分为观察组与对照组,各30例。对照组予以口服质子泵抑制剂治疗,观察组在口服质子泵抑制剂的基础上加用莫沙必利治疗,对比两组治疗效果。结果:观察组症状评分下降程度明显大于对照组,差异显著(P<0.05);对照组治疗有效率为86.7%,与观察组的96.7%相比较,差异显著(P<0.05)。结论:莫沙必利联合质子泵抑制剂治疗胃食管反流病的治疗效果更加优异,患者临床症状改善明显,具有较高的应用价值,值得推广。

Objective： to explore the mo sand shall be joined the proton pump inhibitor clinical curative effect for the treatment of gastroesophageal reflux disease. Selection methods： our hospital during the period of August 2,2014-60 cases of gastroesophageal reflux disease as the research object,its were randomly divided into observation group and control group,30 cases each. Control group oral proton pump inhibitor treatment,observation group on the basis of oral proton pump inhibitors and treatment with moser will benefit,compared two groups of therapeutic effect. Results： the observation group symptom scores decreased significantly greater than the control group,significant difference（ P 〈 0. 05）; The control group treatment effective rate of 86. 7%,compared with 96. 7% of the observation group,significant difference（ P 〈 0. 05）. Conclusion： moser will benefit joint of proton pump inhibitors in the treatment of gastroesophageal reflux disease treatment effect is more outstanding,patients with clinical symptoms improved obviously,has higher application value and is worth promoting.